Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Depressive Disorder, Major Clinical Trial

Official title: Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Status Completed

Clinical Trial Summary

This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

Clinical Trial Description

We hope to learn whether ropinirole CR (controlled release formulation) is safe and effective when taken with an antidepressant to reduce the symptoms of depression. Adults who have a diagnosis of major depression and are currently taking an adequate dose of antidepressant medication will be sought for participation. They will continue to take the antidepressant medication and will receive ropinirole CR, an investigational medication, for eight weeks during which information will be collected about mood and cognitive functioning. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major

• NCT number: NCT00285727
• Study type: Interventional
• Source: Stanford University
• Status: Completed
• Phase: N/A
• Start date: January 2006
• Completion date: October 2007